~13 spots leftby Apr 2026

Renuva Injection for Vocal Cord Paralysis

Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: University of Southern California
Disqualifiers: Pregnancy, Laryngeal infection, Laryngeal conditions, others
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This trial is testing Renuva, a fat tissue-based filler, on patients with vocal cord issues. The goal is to see if it can safely and effectively improve their voice by stimulating new tissue growth in the vocal cords. Renuva is similar to fat injections that have been used since 1987 for vocal cord treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Renuva Allograft Adipose Matrix for vocal cord paralysis?

Research on similar treatments, like autologous fat injections and adipose-derived regenerative cells, shows they can improve voice quality and quality of life in patients with vocal cord paralysis by filling gaps and supporting tissue healing.12345

Is Renuva Injection safe for use in humans?

Research on similar treatments, like human adipose-derived extracellular matrix (ECM) and autologous fat injections, suggests they are generally safe for vocal fold augmentation, showing no significant inflammation or complications in studies.16789

How is the Renuva treatment different from other treatments for vocal cord paralysis?

Renuva is unique because it uses an allograft adipose matrix, which is derived from human fat tissue, to enhance vocal function without the early resorption and morbidity associated with autologous fat injections. This treatment offers greater biostability and avoids the need for liposuction, making it a promising option for stable vocal fold augmentation.1671011

Research Team

Eligibility Criteria

This trial is for adults over 18 with unilateral vocal fold immobility and glottic insufficiency lasting at least two weeks. Participants must consent to follow the study procedures. Pregnant individuals, those with active laryngeal infections or other complex laryngeal conditions, a life expectancy under six months, or allergies to certain anesthetics cannot join.

Inclusion Criteria

I am 18 years old or older.
My voice box has been partly paralyzed for at least 2 weeks.
Willingness to partake in study and follow-up as documented by signed informed consent

Exclusion Criteria

You have had an allergic reaction to lidocaine or similar numbing medicines.
I have had surgery on my voice box.
I have a known throat condition that needs different treatment.
See 3 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a unilateral injection augmentation with allograft adipose matrix injectable (Renuva) in the vocal fold

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at 0, 1, 3, 6, 12, and 18 months

18 months
6 visits (in-person)

Treatment Details

Interventions

  • Renuva Allograft Adipose Matrix (Allograft Adipose Injectable)
Trial OverviewThe trial is testing Renuva Allograft Adipose Matrix as an injectable treatment for glottic insufficiency caused by vocal fold paralysis. Renuva aims to integrate into the tissue without affecting its natural properties and may stimulate healing through growth factors.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Injection of Renuva Allograft adipose matrix in vocal foldExperimental Treatment1 Intervention
Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Southern California

Lead Sponsor

Trials
956
Recruited
1,609,000+
Dr. Samir A. profile image

Dr. Samir A.

University of Southern California

Chief Executive Officer since 2024

PhD in Molecular Biology from the University of Southern California

Dr. Chung profile image

Dr. Chung

University of Southern California

Chief Medical Officer since 2016

MD from UC San Diego

Findings from Research

In a study of 14 patients with unilateral vocal cord paralysis, injection laryngoplasty using micronized AlloDerm significantly improved voice quality, with habitual phonation time increasing from 3.84 to 6.72 seconds and a notable reduction in voice handicap index scores.
The procedure demonstrated a high safety profile, with minimal morbidity and tissue reaction, and 87.5% of patients maintained excellent voice quality at 3 months post-injection, despite some resorption of the material.
A preliminary report on micronized AlloDerm injection laryngoplasty.Pearl, AW., Woo, P., Ostrowski, R., et al.[2022]
In a study of 21 patients with unilateral vocal cord paralysis and cordectomy defects, autologous fat injections led to significant improvements in voice quality and phonatory functions over a mean follow-up of 14 months.
The treatment was particularly effective for patients with unilateral vocal cord paralysis, with 15 out of 18 patients experiencing improvement in swallowing symptoms, indicating its potential as a viable intervention for these conditions.
[Long-term results of intracordal or neocordal autologous fat injection in patients with unilateral vocal cord paralysis and cordectomy].Güven, M., Demir, D., Süoğlu, Y., et al.[2019]
The study shows that ADRC-enriched fat grafts are a safe and effective treatment for glottal gap defects caused by unilateral vocal fold paralysis, with significant improvements in patients' self-perceived voice quality after treatment.
Patients receiving ADRC-enriched grafts reported greater improvements in their voice quality compared to those receiving standard centrifuged autologous fat, indicating a potential advantage of using ADRCs in vocal fold reconstruction.
Injection Laryngoplasty Using Autologous Fat Enriched with Adipose-Derived Regenerative Stem Cells: A Safe Therapeutic Option for the Functional Reconstruction of the Glottal Gap after Unilateral Vocal Fold Paralysis.Lasso, JM., Poletti, D., Scola, B., et al.[2022]

References

A preliminary report on micronized AlloDerm injection laryngoplasty. [2022]
[Long-term results of intracordal or neocordal autologous fat injection in patients with unilateral vocal cord paralysis and cordectomy]. [2019]
Injection Laryngoplasty Using Autologous Fat Enriched with Adipose-Derived Regenerative Stem Cells: A Safe Therapeutic Option for the Functional Reconstruction of the Glottal Gap after Unilateral Vocal Fold Paralysis. [2022]
Bilateral vocal fold injection with autologous fat in patients with vocal fold atrophy with or without sulcus. [2021]
Office-Based Intracordal Hyaluronate Injections Improve Quality of Life in Thoracic-Surgery-Related Unilateral Vocal Fold Paralysis. [2022]
Human Adipose Tissue Derived Extracellular Matrix and Methylcellulose Hydrogels Augments and Regenerates the Paralyzed Vocal Fold. [2018]
Autogenous fat injection for glottic insufficiency: analysis of 101 cases and correlation with patients' self-assessment. [2006]
[Experimental study on adipose-derived stem cells combined with acellular dermal matrix particles for vocal fold injection]. [2011]
Clinical study of injectable collagen scaffold with autologous fat cells for repair of severe vocal fold injury. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Micronized acellular dermal matrix as an efficient expansion substrate and delivery vehicle of adipose-derived stem cells for vocal fold regeneration. [2012]
11.Korea (South)pubmed.ncbi.nlm.nih.gov
Vocal fold injection: review of indications, techniques, and materials for augmentation. [2022]